The Era of the One-Size-Fits-All Cancer Drug Is Ending
The Shift Toward Precision Oncology Pharmaceutical researchers and investors are pivoting away from the pursuit of universal “blockbuster” cancer therapies in favor of highly specialized, targeted treatments, signaling a fundamental shift in oncology as of late 2024. For years, the industry focused on toppling Merck’s Keytruda, a broad-spectrum immunotherapy, but recent clinical data suggests that…